Biotech Stock News (ARWR)(AMGN)(ATHX)(PFE)

Arrowhead Research Corp (NASDAQ:ARWR) On April 13, 2015 Arrowhead announced that it was given the go-ahead by the FDA to begin treating patients in the phase 2b Hepatitis B study. ┬áThe drug compound being used in the study is known as ARC-520 which is an RNAi drug. RNAi stands for RNA interference and these types … Read more